Quest Diagnostics Inc (DGX) Stock Price & Analysis

Quest Diagnostics Inc (DGX) rose 3.71% to USD 204.53 as of June 10, 2026 at 00:38 UTC, according to Nexqual real-time market data.

DGX last closed at USD 197.21; the session ranged USD 196.99–204.84 on volume of 572,007 shares. Market capitalization is $22.64B, with a 52-week range of USD 164.65–213.5 (NYQ). Source: Nexqual, June 10, 2026 at 00:38 UTC.

Key Statistics (as of June 10, 2026 at 00:38 UTC)

Technical Analysis (DGX)

Nexqual's technical model rates DGX "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:38 UTC.

Analyst Ratings (DGX)

Wall Street analysts rate DGX "Buy" based on 16 analysts, with a mean price target of USD 223.44 (range USD 184–245), per Nexqual as of June 10, 2026 at 00:38 UTC.

Earnings (DGX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:38 UTC.

Financials & Fundamentals (DGX)

Source: Nexqual, June 10, 2026 at 00:38 UTC.

Financial Health Score (DGX)

Nexqual rates Quest Diagnostics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:38 UTC.

Ownership (DGX)

Source: Nexqual, June 10, 2026 at 00:38 UTC.

Leadership (DGX)

Quest Diagnostics Inc is led by James E. Davis (age 62), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 00:38 UTC.

Major Backers & Investors (DGX)

Notable institutional backers of Quest Diagnostics Inc include Price (T.Rowe) Associates Inc, JPMorgan, Boston Partners, according to Nexqual as of June 10, 2026 at 00:38 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:38 UTC.

From Quest Diagnostics Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In 2025, our Collaborative Lab Solutions (formerly known as Professional Laboratory Services) offering generated approximately $800 million in revenues and management fees supporting hospitals in the operation of their own labs.
• In 2025, we generated approximately $1.2 billion in revenue from "reference testing," where we perform testing that hospitals do not perform in their own in-hospital labs. • Helping hospitals operate their labs more efficiently.
• Our services primarily are provided under the Quest Diagnostics brand, but we also provide services under other brands, including AmeriPath, ® Dermpath Diagnostics, ® ExamOne, ® and Quanum. ®     We are a leading provider of diagnostic information services in the United States, where we conduct substantially all of our business.
• We see opportunities to bring our experience and expertise in diagnostic information services to markets outside the United States, including leveraging existing facilities to serve new markets. 8 Table of Contents Diagnostic Information Services          Background - clinical testing.

Partnerships

• In 2025, we announced a collaboration with Google to use Google Cloud's data analytics and generative AI to help us streamline our data management, improve data analytics, and personalize the experiences we deliver to patients, providers, and other customers.     We are committed to using AI in an ethical, responsible and compliant way.
• The value delivery side includes sales, laboratory operations, field operations, logistics and client services. 5 Table of Contents Assets and Capabilities that Deliver Value     We collaborate with partners and customers across the healthcare ecosystem to help create a healthier world.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:38 UTC. This page is informational and not investment advice.